Oculomotor nerve paralysis

Summary

Oculomotor nerve paralysis (MONDO:0001309) is a disease (an umbrella term covering 5 Mondo subtypes). A subtype of cranial nerve palsy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	oculomotor nerve paralysis
Mondo ID	MONDO:0001309
Orphanet	98685
DOID	DOID:11550
NCIT	C27597
SNOMED CT	388980004
UMLS	C0028866
MedGen	14459
GARD	0019544
Anatomy (UBERON)	UBERON:0001643
Is cancer (heuristic)	no

Also known as: cranial nerve palsy of oculomotor nerve · IIIrd nerve paralysis · oculomotor nerve cranial nerve palsy · oculomotor nerve paralysis · oculomotor palsy

Disease family

This is a subtype of cranial nerve palsy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › cranial nerve palsy › oculomotor nerve paralysis

Related subtypes (6): fourth cranial nerve palsy, multiple cranial nerve palsy, glossopharyngeal nerve paralysis, Bell’s palsy, abducens nerve palsy, progressive bulbar palsy

Subtypes (5): partial third-nerve palsy, total third-nerve palsy, total internal ophthalmoplegia, nuclear oculomotor paralysis, supranuclear oculomotor palsy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.